Comparing Ibrance vs Pembrolizumab
| Ibrance (palbociclib) | Pembrolizumab |
|
|---|
| Ibrance (palbociclib) | Pembrolizumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Prescription only
Prescribed for Bladder Cancer, Cervical Cancer, Biliary Tract Tumor, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
Related suggestions Breast Cancer
|
|||||||
| More about Ibrance (palbociclib) | More about Pembrolizumab | ||||||||
| Ratings & Reviews | |||||||||
|
Ibrance has an average rating of 6.8 out of 10 from a total of 85 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 29% reported a negative effect. |
Pembrolizumab has an average rating of 5.3 out of 10 from a total of 289 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 44% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Ibrance side effects |
View all Pembrolizumab side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Ibrance prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Keytruda | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
29 hours |
624 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 495 drugs are known to interact with Ibrance:
|
A total of 603 drugs are known to interact with Pembrolizumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
February 03, 2015 |
N/A |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
|
|||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.